Global Custom Market Research Reports Provider Company

phone

Therapix Biosciences Ltd (TRPX) - Financial and Strategic SWOT Analysis Review

  • Published Date: 29 Aug 2018
  • Number of Pages: 45
  • Category: SWOT Analysis
  • Country: Israel
Therapix Biosciences Ltd (TRPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapixs major product candidates include THX-110, for the treatment of tourette syndrome, obstructive sleep apnea and chronic pain; THX-130, for the treatment of mild cognitive impairment and traumatic brain injury; THX-150, for the treatment of infectious diseases; and THX-160, for the treatment of treat pain. The company conducts its clinical programs in collaboration with various pharma companies and institutions. Therapix Biosciences is headquartered in Tel Aviv, Israel.

Therapix Biosciences Ltd Key Recent Developments

Jul 12,2018: Cure acquires Therapixs cannabinoid-based non-pain pipeline
Jul 11,2018: Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences
May 31,2018: Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
May 15,2018: Therapix Biosciences Issues CEOs Letter to Shareholders
May 09,2018: Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
Publisher Name : GlobalData

3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Therapix Biosciences Ltd - Key Facts 6
Therapix Biosciences Ltd - Key Employees 7
Therapix Biosciences Ltd - Key Employee Biographies 8
Therapix Biosciences Ltd - Major Products and Services 9
Therapix Biosciences Ltd - History 10
Therapix Biosciences Ltd - Locations And Subsidiaries 11
Head Office 11
Other Locations & Subsidiaries 11
Section 2 Company Analysis 12
Company Overview 12
Therapix Biosciences Ltd - Business Description 13
Therapix Biosciences Ltd - Corporate Strategy 14
Therapix Biosciences Ltd - SWOT Analysis 15
SWOT Analysis - Overview 15
Therapix Biosciences Ltd - Strengths 15
Therapix Biosciences Ltd - Weaknesses 16
Therapix Biosciences Ltd - Opportunities 17
Therapix Biosciences Ltd - Threats 18
Therapix Biosciences Ltd - Key Competitors 19
Section 3 Company Financial Ratios 20
Financial Ratios - Capital Market Ratios 20
Financial Ratios - Annual Ratios 21
Performance Chart 23
Financial Performance 23
Financial Ratios - Interim Ratios 24
Financial Ratios - Ratio Charts 25
Section 4 Companys Lifesciences Financial Deals and Alliances 26
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27
Therapix Biosciences Ltd, Recent Deals Summary 28
Section 5 Companys Recent Developments 29
Jul 12, 2018: Cure acquires Therapixs cannabinoid-based non-pain pipeline 29
May 31, 2018: Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 30
May 15, 2018: Therapix Biosciences Issues CEOs Letter to Shareholders 32
May 09, 2018: Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange 34
Jan 09, 2018: Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update at the Biotech Showcase 2018 35
Jan 09, 2018: Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update at the Biotech Showcase 2018 36
Nov 10, 2017: Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids 37
Nov 09, 2017: Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update 38
Nov 07, 2017: Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders 39
Nov 02, 2017: Therapix Biosciences Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer 40
Section 6 Appendix 41
Methodology 41
Ratio Definitions 41
About GlobalData 45
Contact Us 45
Disclaimer 45

List Of Tables


Therapix Biosciences Ltd, Key Facts 6
Therapix Biosciences Ltd, Key Employees 7
Therapix Biosciences Ltd, Key Employee Biographies 8
Therapix Biosciences Ltd, Major Products and Services 9
Therapix Biosciences Ltd, History 10
Therapix Biosciences Ltd, Subsidiaries 11
Therapix Biosciences Ltd, Key Competitors 19
Therapix Biosciences Ltd, Ratios based on current share price 20
Therapix Biosciences Ltd, Annual Ratios 21
Therapix Biosciences Ltd, Annual Ratios (Cont...1) 22
Therapix Biosciences Ltd, Interim Ratios 24
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 27
Therapix Biosciences Ltd, Recent Deals Summary 28
Currency Codes 41
Capital Market Ratios 41
Equity Ratios 42
Profitability Ratios 42
Cost Ratios 43
Liquidity Ratios 43
Leverage Ratios 44
Efficiency Ratios 44

List Of Figures


Therapix Biosciences Ltd, Performance Chart (2013 - 2017) 23
Therapix Biosciences Ltd, Ratio Charts 25
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 26
Therapix Biosciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 27

Royal Mail plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

View Report

Leclanche SA (LECN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

View Report

NEC Corp (6701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports